Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - ethyl ester of c14 & c22 mixed fatty acids; potassium salt of castor oil fatty acids - emulsifiable concentrate - ethyl ester of c14 & c22 mixed fatty acids acid-fatty active 712.0 g/l; potassium salt of castor oil fatty acids mineral-potassium active 62.0 g/l - plant regulator - grape - gordo and waltham | grape - sultana | grapevine - promote fruit drying

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nestle purina petcare a div of nestle australia ltd - salicylic acid; triclosan - shampoo - salicylic acid phenol active 4.0 mg/ml; triclosan phenol active 5.0 mg/ml - dermatological preps. - dog | bitch | castrate | puppy - dermatoses | dry skin | eczema

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

victorian chemical company proprietary limited - ethyl and methyl esters of fatty acids - emulsifiable concentrate - ethyl and methyl esters of fatty acids acid-fatty active 596.0 g/l - plant regulator - grape - gordo and waltham - post harvest | grape - sultana | grape - sultana - post harvest | grapevine - promote fruit drying

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

conquest crop protection pty ltd - glyphosate present as the mono-ammonium salt - water soluble granules - glyphosate present as the mono-ammonium salt glycine active 700.0 g/kg - herbicide

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - budesonide, quantity: 320 microgram; formoterol fumarate dihydrate, quantity: 9 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma: duoresp spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration).,duoresp spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,chronic obstructive pulmonary disease (copd): duoresp spiromax is indicated for the symptomatic treatment of moderate to severe copd (fev1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. duoresp spiromax is not indicated for the initiation of bronchodilator therapy in copd.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma: duoresp spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration).,duoresp spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,chronic obstructive pulmonary disease (copd): duoresp spiromax is indicated for the symptomatic treatment of moderate to severe copd (fev1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. duoresp spiromax is not indicated for the initiation of bronchodilator therapy in copd.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - budesonide, quantity: 320 microgram; formoterol fumarate dihydrate, quantity: 9 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma: biresp spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk and exacerbations (see section 4.2 dose and method of administration).,biresp spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,chronic obstructive pulmonary disease (copd): biresp spiromax is indicated for the symptomatic treatment of moderate to severe copd (fev1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. biresp spiromax is not indicated for the initiation of bronchodilator therapy in copd.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma: biresp spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk and exacerbations (see section 4.2 dose and method of administration).,biresp spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,chronic obstructive pulmonary disease (copd): biresp spiromax is indicated for the symptomatic treatment of moderate to severe copd (fev1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. biresp spiromax is not indicated for the initiation of bronchodilator therapy in copd.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - aclidinium bromide, quantity: 0.4 mg/actuation; formoterol fumarate dihydrate, quantity: 0.012 mg/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - brimica genuair 340/12 is indicated as a long-term twice daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

ABD - İngilizce - NLM (National Library of Medicine)

dentsply llc, professional division, trading as "sultan healthcare" - guaiacol (unii: 6jka7mah9c) (guaiacol - unii:6jka7mah9c), eugenol (unii: 3t8h1794qw) (eugenol - unii:3t8h1794qw) - guaiacol 0.0416 g in 1 g - indicated for the relief of symptoms associated with post-extraction alveolar osteitis ("dry socket syndrome"). this product should not be used with individuals with known sensitivities to guaicol or eugenol. this product should not be used with individuals who are pregnant or suspected to be pregnant without a prior physician consultation.